期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 14, 期 6, 页码 668-675出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurjhf/hfs061
关键词
Aldosterone; Antagonist; Chronic kidney disease; Heart failure; Mineralocorticoid receptor
资金
- Bayer HealthCare AG
- Bayer
- Pfizer
- Merck
- Novartis
- Takeda
- AstraZeneca
- Lilly
- GE Healthcare
- Relypsa
- BG Medicine
- Amorcyte
- Cytopherx
- Aurasense
- Medtronic
- Forest Laboratories
- Novartis Pharma AG
- Sanofi-Aventis
BAY 94-8862 is a novel, non-steroidal, mineralocorticoid receptor antagonist with greater selectivity than spironolactone and stronger mineralocorticoid receptor binding affinity than eplerenone. The aims of the MinerAlocorticoid Receptor Antagonist Tolerability Study (ARTS; NCT01345656) are to evaluate the safety and tolerability of BAY 94-8862 in patients with heart failure associated with a reduced left ventricular ejection fraction (HFREF) and chronic kidney disease (CKD), and to examine the effects on biomarkers of cardiac and renal function. ARTS is a multicentre, randomized, double-blind, placebo-controlled, parallel-group study divided into two parts. In part A, oral BAY 94-8862 [2.5, 5, or 10 mg once daily (o.d.)] is compared with placebo in approximate to 60 patients with HFREF and mild CKD. Outcome measures include serum potassium concentration, biomarkers of renal injury, estimated glomerular filtration rate (eGFR), and albuminuria. Part B compares BAY 94-8862 (2.5, 5, or 10 mg o.d., or 5 mg twice daily), placebo, and open-label spironolactone (2550 mg o.d.) in approximate to 360 patients with HFREF and moderate CKD. Outcome measures include the change in serum potassium concentration with BAY 94-8862 vs. placebo (primary endpoint) and vs. spironolactone, safety and tolerability, biomarkers of cardiac and renal function or injury, eGFR, and albuminuria. BAY 94-8862 pharmacokinetics are also assessed. ARTS is the first phase II clinical trial of BAY 94-8862 and is expected to provide a wealth of information on BAY 94-8862 in patients with HFREF and CKD, including the optimal dose range for further studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据